Skip to content

Bionano Declares Launch of Subsequent-Era Variations of its Reagent Kits and Chip Consumable, Together with Updates to its Instrument Management and Bionano Entry Software program for the Optical Genome Mapping Workflow

Bionano Genomics

  • Bionano Prep SP-G2 (SP-G2) equipment affords greater gDNA high quality, improved ease-of-use and elevated DNA throughput

  • Bionano Prep Direct Label and Stain-G2 (DLS-G2) equipment affords elevated reagent stability and labeling effectivity leading to considerably quicker pattern to outcomes workflow

  • Saphyr Chip® G3.3, instrument management software program (ICS) model 5.3 and Bionano Entry™ software program model 1.7.2 supply enhanced evaporation management and workflow robustness enabling for extra excessive protection samples to be run per week

SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (BNGO right this moment introduced the launch of a number of new merchandise and developments for its optical genome mapping (OGM) workflow that provide enhanced robustness in pattern preparation, decreased turnaround time for DNA labeling and imaging, and enhancements in throughput and high quality metrics.The brand new variations of Bionano’s pattern prep kits, chips and instrument software program handle buyer suggestions and may enhance the efficiency in routine greater quantity genome evaluation purposes.

Bionano’s pattern prep kits are used to extract and label ultra-high molecular weight (UHMW) DNA to be used on the Saphyr® system. These kits are optimized for performing Bionano GMO purposes on a wide range of pattern sorts. Era 2 kits will help blood samples, cell traces, and bone marrow aspirates, with variations for tissue and tumor samples anticipated later in 2023. The Bionano Prep SP-G2 (SP-G2) and Bionano Prep Direct Label and Stain (DLS-G2) ) kits have additionally elevated in dimension from 10-reaction to 12-reaction kits, an improve that higher matches the corporate’s chip consumables.

The SP-G2 equipment enhances UHMW DNA isolation and allows greater pattern success charges, fewer consumer errors and extra knowledge generated per run. One of many important enhancements to pattern preparation is the potential to isolate DNA of upper high quality, particularly for marginal samples. The brand new protocol can even remove time and course of constraints, making the lysis step extra user-friendly and higher optimized for runs with completely different pattern sorts, which permits customers to batch as much as six samples concurrently. These enhancements in chemistry can finally end in elevated DNA throughput for extra knowledge generated per pattern run. As well as, a by-product of the SP-G2 equipment helps Hamilton’s Lengthy String Vantage automated UHMW DNA isolation.

Bionano’s DLS-G2 equipment allows labeling to be accomplished in as little as 5 hours for same-day loading of labeled DNA on the Saphyr® instrument. This improved chemistry can allow an total discount in turnaround (or pattern to reply) time and make it potential to get excessive depth solutions for most cancers samples in as little as three days. Bionano has elevated reagent stability from 9 months to 1 yr for the DLS-G2 equipment, to be per the SP-G2 equipment, which may end up in much less reagent wastage and extra utility over an extended time period.

The Saphyr Chip® G3.3, a brand new model of the instrument management software program (ICS v5.3) and a brand new model of Bionano Entry™ (v.1.7.2), allow improved throughput and success charges when two Saphyr Chips are loaded in parallel, permitting three to 6 extra samples to be processed per work week. These throughput enhancements end result from a discount in pattern evaporation and improve the reliability of pattern loading and efficiency on the Saphyr instrument. Larger throughput additionally ends in higher first-pass yields and will remove the danger of pattern depletion when working with complicated, longer scan-time samples, like these in most cancers analysis or cell bioprocessing. ICS v5.3 help for the Saphyr Chip G3.3 improves consistency of throughput throughout runs in addition to alignment robustness.

Erik Holmlin, PhD, president and chief govt officer of Bionano, commented, “With these product launches we’re considerably increasing the genome evaluation capabilities obtainable to the medical and translational analysis communities. We look ahead to seeing clients profit from these options within the coming months, which we consider can cut back time-to-results and make OGM efficiency even higher. We consider these enhancements can allow better detection of structural variants of every type related to genetic illnesses and complicated issues like most cancers.”

About Bionano Genomics

Bionano Genomics is a supplier of genome evaluation options that may allow researchers and clinicians to disclose solutions to difficult questions in biology and medication. The Firm’s mission is to remodel the way in which the world sees
the genome by OGM options, diagnostic providers and software program. The Firm affords OGM options for purposes throughout fundamental, translational and medical analysis. By way of its Lineagen, Inc. d/b/a Bionano Laboratories enterprise, the Firm additionally gives diagnostic testing for sufferers with medical shows per autism spectrum dysfunction and different neurodevelopmental disabilities. By way of its BioDiscovery enterprise, the Firm additionally affords an industry-leading, platform-agnostic software program answer, which integrates next-generation sequencing and microarray knowledge designed to supply evaluation, visualization, interpretation and reporting of copy quantity variants, single-nucleotide variants and absence of heterozygosity throughout the genome in a single consolidated view. For extra data, go to www.bionanogenomics.com, www.bionanolaboratories.com or biodiscovery.com

Ahead-Trying Statements of Bionano Genomics

This press launch comprises forward-looking statements inside the that means of the Non-public Securities Litigation Reform Act of 1995. Phrases equivalent to “consider,” “can,” “could,” “potential,” “will” and comparable expressions (in addition to different phrases or expressions referencing future occasions, situations or circumstances) convey uncertainty of future occasions or outcomes and are supposed to determine these forward-looking statements. Ahead-looking statements embody statements concerning our intentions, beliefs, projections, outlook, analyzes or present expectations regarding, amongst different issues, the potential of the SP-G2 and DLS-G2 kits to make enhancements to pattern OGM preparation and end result within the isolation and preparation of DNA with greater dimension and high quality, and enhance pattern success charges; the power of ICS v5.3 and the Saphyr Chip G3.3 to enhance consistency of throughput throughout runs in addition to alignment robustness; the power of the Saphyr Chip G3.3 to stop pattern evaporation and improve the reliability of pattern loading and efficiency on the Saphyr instrument, and end in greater first-pass yields or remove the danger of pattern depletion when working with complicated, longer scan- time samples; and the power of OGM to precisely detect genetic issues, together with structural variants, copy quantity variants, repeat expansions better than 500bp and Fragile X syndrome, and, as a single know-how, to end in a workflow that’s cost-effective, extremely delicate and has a quicker time to outcomes than conventional cytogenetic strategies. Every of those forward-looking statements includes dangers and uncertainties. Precise outcomes or developments could differ materially from these projected or implied in these forward-looking statements. Elements which will trigger such a distinction embody the dangers and uncertainties related to: the impression of geopolitical and macroeconomic developments, equivalent to the continued Ukraine-Russian battle, and associated sanctions, and the COVID-19 pandemic, on our enterprise and the worldwide economic system ; the failure of the SP-G2 and DLS-G2 kits to make enhancements to pattern OGM preparation and end result within the isolation and preparation of DNA with greater dimension and high quality, and enhance pattern success charges; the failure of ICS v5.3 and the Saphyr Chip G3.3 to enhance consistency of throughput throughout runs in addition to alignment robustness; the failure of the Saphyr Chip G3.3 to stop pattern evaporation and improve the reliability of pattern loading and efficiency on the Saphyr instrument, and end in greater first-pass yields or remove the danger of pattern depletion when working with complicated, longer scan- time samples; common market situations; modifications within the aggressive panorama and the introduction of aggressive applied sciences or enhancements to present applied sciences; modifications in our strategic and business plans; our skill to acquire adequate financing to fund our strategic plans and commercialization efforts; the power of medical and analysis establishments to acquire funding to help adoption or continued use of our applied sciences; and the dangers and uncertainties related to our enterprise and monetary situation on the whole, together with the dangers and uncertainties described in our filings with the Securities and Change Fee, together with, with out limitation, our Annual Report on Kind 10-Okay for the yr ended December 31 , 2021 and in different filings subsequently made by us with the Securities and Change Fee. All forward-looking statements contained on this press launch communicate solely as of the date on which they have been made and are based mostly on administration’s assumptions and estimates as of such date. We don’t undertake any obligation to publicly replace any forward-looking statements, whether or not because of the receipt of recent data, the prevalence of future occasions or in any other case.

CONTACTS
Firm Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com

Investor Relations:
Amy Conrad
Juniper Level
+1 (858) 366-3243
amy@juniper-point.com

Leave a Reply

Your email address will not be published. Required fields are marked *